Pharmaceutical composition for preventing or treating heart failure

A method for treating or preventing heart failure, comprising administrating a pharmaceutical composition comprising an expression vector containing a DNA sequence encoding RNA comprising a sense strand sequence of consecutive 18 to 29 nucleotides from angiopoietin-like protein 2 mRNA or the alternative splicing type RNA thereof, and an antisense strand sequence complementary to the sense strand sequence under control of a promoter and a pharmaceutically acceptable carrier to a human subject in need of treatment or prevention of heart failure in an amount effective for treating or preventing heart failure of the subject,

• wherein the expression vector has delivery selectivity into cardiomyocytes and the sense strand sequence and antisense strand sequence are adapted for use in preparing siRNA, wherein the siRNA, when transduced into a cardiomyocyte, suppresses expression of the angiopoietin-like protein 2 gene in the cell.

A method for treating or preventing heart failure, comprising administrating a pharmaceutical composition for treating or preventing heart failure comprising siRNA comprising a sense strand sequence of consecutive 18 to 29 nucleotides from angiopoietin-like protein 2 mRNA or alternative splicing type RNA thereof and an antisense strand sequence complementary to the sense strand sequence and a pharmaceutically acceptable carrier to a human subject in need of treatment or prevention of heart failure in an amount effective for treating or preventing heart failure of the subject,

• wherein the siRNA targets angiopoietin-like protein 2 gene in cardiomyocytes and is adapted for use such that the siRNA, when transduced into the cardiomyocyte cell, suppresses expression of the angiopoietin-like protein 2 gene in the cell.